Compare Amphastar Pharmaceuticals Inc (AMPH) vs Mercadolibre Inc (MELI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Mercadolibre Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Mercadolibre Inc trades at $1,853.18 (market cap $93.90B). The key difference: Mercadolibre Inc is far larger — about 113.7× Amphastar Pharmaceuticals Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | MELI | |
|---|---|---|
Market Cap | $826.08M | $93.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $2.51K |
52-Week Low | $16.87 | $1.55K |
Enterprise Value | $1.22B | $100.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
MercadoLibre (MELI) trades at $1,852.22, up 2.46% today, with a bullish technical signal from moving averages and strong analyst support (23 buy, 0 sell). Revenue grew to $28.89B in 2025, though net income margin compressed to 6.04% amid heavy investment. Recent news highlights investigations by law firms and debates over profitability versus growth, while cash flow from operations surged to $12.12B.
Outlook remains positive given dominant Latin American e-commerce position and 49% revenue growth, but risks include margin pressure from capex, legal scrutiny, and high valuation multiples. The consensus price target of $2,230 implies ~20% upside, contingent on execution amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
